Medical Developments International Limited (AU:MVP)
ASX:MVP
Want to see AU:MVP full AI Analyst Report?
Top Page
Medical Developments International Limited
(Sydney:MVP)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$0.39
▼(-29.09% Downside)
Action:Reiterated
Date:04/29/26
The score is held back primarily by weak profitability and concerning cash flow trends despite a low-leverage balance sheet. Technicals are mildly supportive in the short term, but longer-term moving averages still indicate a downtrend. The latest earnings call added some support via revenue growth, margin/pricing initiatives, and improved cash flow, though guidance flagged continued Respiratory softness and cost/FX headwinds. Valuation remains difficult to justify on earnings due to the negative P/E and no dividend yield data.
Positive Factors
High Gross Margin
A 75% gross margin indicates durable product-level economics and manufacturing/sku advantages for Penthrox and consumables. Such high gross margins provide capacity to absorb input cost inflation, fund commercial expansion and evidence generation, and sustain profitability as volumes scale.
Negative Factors
Very Thin Profitability
Near-zero EBIT and net margins show limited ability to convert strong gross profit into earnings after operating costs. This weak operational profitability makes results highly sensitive to FX, tariffs, and higher marketing or transition costs, constraining durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A 75% gross margin indicates durable product-level economics and manufacturing/sku advantages for Penthrox and consumables. Such high gross margins provide capacity to absorb input cost inflation, fund commercial expansion and evidence generation, and sustain profitability as volumes scale.
Read all positive factors
Medical Developments International Limited (MVP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$42.25M
Dividend YieldN/A
Average Volume (3M)118.82K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue Growth6.80%
EPS Growth98.84%
CountryAU
Employees68
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding112,658,325
10 Day Avg. Volume79,692
30 Day Avg. Volume118,816
Financial Highlights & Ratios
PEG Ratio-6.86
Price to Book (P/B)1.17
Price to Sales (P/S)1.65
P/FCF Ratio-132.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.85Price Target Upside54.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$42.80M
Medical Developments International Limited Business Overview & Revenue Model
Company Description
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divide...
How the Company Makes Money
Medical Developments International makes money primarily by selling its products to healthcare systems and distributors, with revenue driven mainly by its pain management portfolio. The largest and most prominent revenue stream is the sale of Pent...
Medical Developments International Limited Earnings Call Summary
Earnings Call Date:Feb 18, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Neutral
The call presented a mix of positive operational progress and near-term headwinds. Highlights include 8% group revenue growth, strong Pain Management momentum (+18%), positive operating cash flow, published pediatric data and imminent Europe pediatric approvals, pricing actions expected to add ~A$1m margin, and early partner traction (France +10%). Offsetting these are meaningful Respiratory weakness driven by a 16% U.S. decline and overall segment -10%, a ~$1.1m FX drag, short-term earnings impact from partner transitions (~$600k) and higher medical/commercial spending (~$500k), plus U.S. tariff uncertainty and market valuation concerns. On balance the company shows clear strategic progress and improved underlying performance when adjusted for FX, but near-term respiratory softness and transition-related impacts temper the outlook.Positive Updates
Group Revenue Growth
Group revenue increased 8% in FY '26 H1 versus prior period, reflecting stronger underlying performance.
Negative Updates
Respiratory Segment Weakness
Respiratory revenues declined 10% overall, driven by particularly soft demand in the U.S. where revenues fell ~16%, and management expects near‑term softness to persist, weighing on second half earnings.
Read all updates
Q2-2026 Updates
Positive
Negative
Group Revenue Growth
Group revenue increased 8% in FY '26 H1 versus prior period, reflecting stronger underlying performance.
Read all positive updates
Company Guidance
The company guided that it expects to finalize pediatric approvals in Europe (device approval received; remaining country‑level medicines approvals—including the important U.K. market—targeted by August) and to support the subsequent label launch while continuing targeted medical/commercial investment and real‑world evidence generation (including a health‑economic study due by end FY‑26); financially it cautioned that seasonally softer Respiratory demand (U.S. respiratory sales -16% H1; overall Respiratory down 10% H1) is expected to persist and drive second‑half earnings lower than H1, even as Pain Management momentum (group revenue +8% H1; Pain +18% H1; Europe underlying demand +10%—U.K./Ireland +8%, France +10%, Nordics +16%; Australia Pain revenue +18%, volumes +9%, hospital +26%) supports growth; management reiterated margin focus with an expected ~A$1.0m FY‑26 margin uplift from Australian pricing (H1 benefits included +A$700k from higher Penthrox pricing and ~A$1.0m net earnings benefit from higher volumes/pricing, partly offset by A$600k transition costs and A$500k higher spend, and A$1.1m FX headwinds), reported positive operating cash flow of A$300k (A$1.0m improvement YoY) and A$16.9m cash balance to fund the plan.Medical Developments International Limited Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
65
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.64M | 39.06M | 33.15M | 32.34M | 21.94M | 25.27M |
| Gross Profit | 21.42M | 29.43M | 24.37M | -2.52M | -3.06M | 16.67M |
| EBITDA | 1.98M | 1.67M | -29.45M | -4.28M | -12.86M | -11.11M |
| Net Income | -436.00K | 94.00K | -40.99M | -5.61M | -12.41M | -12.56M |
Balance Sheet | ||||||
| Total Assets | 63.57M | 66.40M | 59.16M | 109.49M | 101.36M | 100.17M |
| Cash, Cash Equivalents and Short-Term Investments | 16.88M | 17.84M | 9.73M | 24.66M | 20.40M | 36.28M |
| Total Debt | 3.34M | 1.99M | 2.29M | 2.56M | 2.81M | 3.05M |
| Total Liabilities | 8.80M | 11.29M | 13.43M | 28.17M | 44.06M | 31.87M |
| Stockholders Equity | 54.77M | 55.10M | 45.73M | 81.31M | 57.30M | 68.30M |
Cash Flow | ||||||
| Free Cash Flow | 486.00K | -486.00K | -13.95M | -24.16M | -15.94M | -15.37M |
| Operating Cash Flow | 993.00K | -43.00K | -10.78M | -16.50M | -10.72M | -8.81M |
| Investing Cash Flow | -863.00K | -1.04M | -3.17M | -7.67M | -5.21M | -6.56M |
| Financing Cash Flow | -787.00K | 8.68M | -807.00K | 28.06M | 142.00K | 36.12M |
Medical Developments International Limited Technical Analysis
Positive
0.55
Price Trends
0.41
Positive
0.42
Negative
0.51
Negative
Market Momentum
>-0.01
Negative
60.08
Neutral
50.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Positive. The current price of 0.55 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.41, and above the 200-day MA of 0.51, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 60.08 is Neutral, neither overbought nor oversold. The STOCH value of 50.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVP.
Medical Developments International Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$20.21M | 25.77 | 1.66% | 3.28% | 2.11% | -64.71% | |
55 Neutral | AU$42.25M | -98.19 | -0.79% | ― | 6.80% | 98.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$66.42M | 2.83 | 10.34% | ― | 15.21% | -141.82% | |
42 Neutral | AU$13.57M | -2.24 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:MVP
Medical Developments International Limited
0.42
-0.15
-27.19%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.02
-23.00%
AU:IDT
IDT Australia Limited
0.03
-0.06
-62.22%
AU:VIT
Cronos Australia Ltd.
0.03
-0.03
-50.85%
Medical Developments International Limited Corporate Events
Medical Developments International Lifts Cash Flow on Strong Penthrox Demand
Apr 23, 2026
Medical Developments International reported group revenue of $10.5 million for the March quarter and $32.1 million year-to-date, driven by strong growth in its Pain Management segment and higher Penthrox volumes in Australia and Europe. The compan...
Medical Developments International Reports Lapse of 575,235 Performance Rights
Apr 20, 2026
Medical Developments International Limited has notified the market that 575,235 performance rights, trading under the ASX security code MVPAD, have ceased. The securities lapsed on 17 April 2026 due to the expiry of the performance rights without ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.